文献速递肥胖与代谢综合征糖尿病

代谢功能障碍相关脂肪性肝病(MAFLD)与死亡率的关系:旁观者而非驱动因素

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究基于结直肠癌筛查项目的单中心队列,纳入4718名45至80岁受试者,按BMI和MAFLD状态分组,通过国家医保系统系统读取死亡信息,超声诊断脂肪肝。中位随访7.5年,278例死亡,MAFLD的存在并未增加死亡率,其与不良结局的关联由年龄和代谢合并症(尤其是糖尿病)驱动。

要点

  • MAFLD存在与否不增加45至80岁人群的死亡率。
  • 瘦型MAFLD的生存率在数值上最差,但无统计学意义。
  • MAFLD与不良结局的关联由年龄和代谢合并症驱动。

核心结论

  • 在45至80岁人群中,MAFLD的存在不增加死亡率。

研究设计与样本

  • 单中心队列研究,基于结直肠癌筛查项目,纳入4718名45至80岁受试者。

主要发现

  • 总体脂肪肝患病率为47.9%,中位随访7.5年(IQR 4.0-9.6)期间278例死亡(5.9%)。
  • 5年总生存率在各组间相似(93.9%-98.2%),瘦型MAFLD生存率数值上最差。
  • 瘦型和超重MAFLD患者结局数值上劣于无MAFLD者,但关联由年龄和代谢合并症(主要为糖尿病)驱动。

临床怎么用

  • 对于MAFLD患者,应重点关注年龄和代谢合并症(尤其是糖尿病)的管理,而非仅针对脂肪肝本身。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Recently, the novel metabolic dysfunction-associated fatty liver disease (MAFLD) definition has been introduced. OBJECTIVE: To assess the relevance of MAFLD for mortality. METHODS: Single-center cohort-study using colorectal cancer screening program involving 4718 subjects aged 45 to 80 who were grouped according to their body mass index (BMI) and the presence or absence of MAFLD. Mortality was compared among these groups by performing a systematic read-out of the national health insurance system, fatty liver (FL) was diagnosed using ultrasound. RESULTS: Overall prevalence of FL was 47.9%: 1200 (25.4%) patients were lean (BMI < 25 kg/m2) and did not have MAFLD, 73 (1.5%) patients were lean and had nonalcoholic fatty liver disease but did not fulfill criteria for MAFLD, and 221 (4.7%) patients were lean and fulfilled criteria for MAFLD. Additionally, 1043 (22.1%) and 925 (19.6%) subjects had MAFLD with overweight (BMI 25-30 kg/m2) and obesity (BMI ≥ 30 kg/m2), respectively, while 1041 (22.1%) and 215 (4.6%) had overweight and obesity, respectively, without FL. During a median follow-up of 7.5 (interquartile range: 4.0-9.6) years, 278 deaths (5.9%) occurred. Of these, 98 (2.1%) were cancer-related, 65 (1.4%) were cardiovascular, and 17 (0.4%) were liver-related. Overall survival was similar between patient strata (after 5 years: 93.9%-98.2%) with lean MAFLD having the numerically worst survival. Although lean and overweight patients with MAFLD had a numerically worse outcome compared to their non-MAFLD counterparts, this association was driven by age and metabolic comorbidities (predominantly diabetes) rather than the presence of MAFLD. CONCLUSION: Presence of MAFLD does not increase mortality in a cohort of individuals aged 45 to 80 years.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Semmler G, Wernly S, Bachmayer S, et al. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality. J Clin Endocrinol Metab. 2021. PMID: 33982065. doi:10.1210/clinem/dgab339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。